Lexeo Therapeutics (LXEO) Leases (2022 - 2026)

Lexeo Therapeutics' Leases history runs 5 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Leases rose 348.19% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 348.19% YoY), while the FY2025 annual figure was $6.6 million, down 18.48% from the prior year.
• Leases came in at $6.2 million for Q1 2026 at Lexeo Therapeutics, down from $6.6 million in the prior quarter.
• In the past five years, Leases ranged from a high of $10.7 million in Q4 2022 to a low of $1.2 million in Q3 2025.
• A 5-year average of $4.9 million and a median of $4.0 million in 2023 frame the typical range for Leases.
• Across the five-year window, Leases soared 357.93% in 2024 and tumbled 85.54% in 2025, its largest moves.
• Lexeo Therapeutics' Leases stood at $10.7 million in 2022, then plunged by 83.54% to $1.8 million in 2023, then soared by 357.69% to $8.1 million in 2024, then decreased by 18.48% to $6.6 million in 2025, then retreated by 5.97% to $6.2 million in 2026.
• According to Business Quant data, Leases over the past three periods registered $6.2 million, $6.6 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison